Compare Genuine Parts Company (GPC) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Genuine Parts Company vs Sana Biotechnology Inc — how do they compare? Genuine Parts Company trades at $126.99 (market cap $17.67B), while Sana Biotechnology Inc trades at $2.8 (market cap $836.71M). The key difference: Genuine Parts Company is far larger — about 21.1× Sana Biotechnology Inc's market cap, and Genuine Parts Company pays a 3.32% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Genuine Parts Company for 75 Days and Sana Biotechnology Inc for 23 Days on average.
| GPC | SANA | |
|---|---|---|
Market Cap | $17.67B | $836.71M |
Volume | 1,079,458 | 4,507,444 |
Sector | Consumer Cyclical | Health |
52-Week High | $149.26 | $5.92 |
52-Week Low | $92.47 | $2.68 |
Typical Hold Time | 75 Days | 23 Days |
Enterprise Value | $23.76B | $749.96M |
Dividend Yield | 3.32% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GPC trades at $127.16, up 1.4% today, near its pivot point of $127 with technical indicators showing a bullish trend. The company reported mixed quarterly earnings, beating in Q1 and Q2 2026 but missing in Q4 2025, with Q3 2026 results due October 20. Revenue growth is steady, but net income margins have compressed significantly to 0.13% in 2025. Analysts maintain a consensus price target of $145.75, with 43% recommending Buy. Key developments include the planned spinoff of its industrial unit, Motion, scheduled for Q1 2027.
The outlook for GPC is cautiously optimistic, driven by the potential value unlock from the corporate split and its position in the resilient automotive aftermarket. However, thin profit margins and rising debt levels pose risks. The stock offers a dividend yield supported by its Dividend King status, but investors should weigh execution risks around the separation against the prospect of segment-specific reratings.
SANA Biotechnology trades at $2.84, up 4.41% today, while showing bearish technical signals with moving averages indicating selling pressure. The company remains pre-revenue with significant losses (-$244.17M net income in 2025) and negative cash flow from operations. Recent investor conference presentations highlight ongoing development of engineered cell therapies, though earnings have missed expectations in two of the last three quarters.
Despite analyst optimism (82% buy ratings), SANA faces substantial execution risk as a clinical-stage biotech with no current revenue and high cash burn. The stock's outlook depends heavily on clinical trial progress and future funding needs, with current valuation at 5.41x book value despite negative profitability metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Genuine Parts Company
Genuine Parts sells automotive parts (about two thirds of net sales) and industrial components. The company sells vehicle parts to commercial and retail customers through roughly 9,700 stores worldwide, most of which are independently owned. Its industrial unit, primarily operating under the Motion Industries banner in the United States, supplies bearings, power transmission, industrial automation, hydraulic, and pneumatic components to maintenance, repair, and OEM clients.
Read more on GPC →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
